Premium
GLOFITAMAB STEP‐UP DOSING: UPDATED EFFICACY DATA SHOW HIGH COMPLETE RESPONSE RATES IN HEAVILY PRETREATED RELAPSED/REFRACTORY (R/R) NON‐HODGKIN LYMPHOMA (NHL) PATIENTS
Author(s) -
CarloStella C,
Hutchings M,
Offner F. C,
Morschhauser F,
Bachy E,
Crump M,
Sureda A,
Iacoboni G,
Haioun C,
PerezCallejo D,
Lundberg L,
Relf J,
Clark E,
Carlile D,
Piccione E,
Belousov A,
Humphrey K,
Dickinson M. J
Publication year - 2021
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.15_2879
Subject(s) - medicine , dosing , refractory (planetary science) , cytokine release syndrome , gastroenterology , rituximab , neutropenia , lymphoma , surgery , chemotherapy , cancer , immunotherapy , physics , chimeric antigen receptor , astrobiology